Lipid A is the active moiety of lipopolysaccharide (LPS, endotoxin), a bacterial product important in the pathogenesis of Gram-negative sepsis. Lipid A activates phagocytes through a defined receptor system. While LBP and CD14 enhance LPS responses, two proteins are obligatory for signal transduction: Toll-like receptor (TLR) 4 and MD-2. This multimeric receptor utilizes all four TLR-adapter molecules: MyD88, Mal, TRAM and TRIF, giving TLR4/MD-2 a complexity that is unrivaled by other TLRs. In the past, we focused on three aspects of TLR4 activation: first, what we could learn about TLR4 by comparing it to other TLRs. Second, how MD-2 binds LPS. Third, how Mal and TRAM interact with TLR4. In the next funding period, our goal is to determine how TLR4 achieves an active state (i.e., one that transduces signals) and to better delineate how TIR domain containing adapters modulate gene expression. We will focus on techniques with which we have become expert: the creation of novel cell lines, the production of recombinant TLRs, confocal and electron microscopy, microarray analysis and the exploitation of transgenic mice. In the Aim 1, we propose to identify what constitutes an active TLR4/MD-2 receptor complex. We will focus on conformational changes induced by ligands, as well as the dimerization status of TLR4/MD-2.
In Aim 2, we will establish the rules for adapter molecule engagement. We will perform a much-overdue global analysis of downstream signaling events specifically mediated by adapter molecules by RNA profiling LPS-stimulated macrophages from TLR adapter knockout mice. These studies will be validated by real time PCR, and test the canonical model (which we hypothesize to be flawed) that MyD88/Mal activates proinflammatory genes while the remained of gene expression is subserved via TRAM/TRIF. We will analyze the functions of known polymorphisms associated with Mal and MyD88 in macrophage cell lines derived from KO mice, and determine how these polymorphisms influence adapter molecule recruitment.
In Aim 3, we will focus on MD-2, the binding portion of TLR4/MD-2, which we have purified to homogeneity in its monomeric (active) state. We will use biophysical approaches (e.g., circular dichroism, FLIM) to assess ligand-induced conformational changes in MD-2 and TLR4. We will combine mutagenesis and forward genetic screening to identify mutants of MD-2 that are constitutively active, and determine their structure/function both empirically and in silico by building on the recently resolved crystal for MD-2. Finally, virtually nothing is known about the regulation and role of MD-2 during inflammatory states in vivo. We will expand upon the limited number of reagents available for MD-2 by generating anti-mouse MD-2 mAbs. We also propose to engineer a transgenic mouse in which GFP is under the control of the MD-2 promoter and natural MD-2 will be epitope tagged with FLAG. We will determine which cells produce MD-2 and how much is produced during inflammation. Ultimately, we believe that an improved understanding of TLR4/MD-2 biology will lead to an amelioration of the morbidity and mortality of sepsis. Toll-like receptors (TLRs) are molecules on white blood cells that recognize microbes and lead to immune defense and inflammation. There are many diseases caused by TLR activation, but none is more deadly than LPS (lipid A) induced sepsis, which is caused by activation of the TLR4/MD-2 receptor complex. We propose to learn how the TLR4/MD-2 receptor is activated by LPS (lipid A), in order that the high mortality and morbidity of sepsis can be ameliorated.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Dunsmore, Sarah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Kalantari, Parisa; Harandi, Omid F; Agarwal, Sarika et al. (2017) miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN). J Biol Chem 292:5634-5644
Andrade, Warrison A; Agarwal, Sarika; Mo, Shunyan et al. (2016) Type I Interferon Induction by Neisseria gonorrhoeae: Dual Requirement of Cyclic GMP-AMP Synthase and Toll-like Receptor 4. Cell Rep 15:2438-48
Shaughnessy, Jutamas; Gulati, Sunita; Agarwal, Sarika et al. (2016) A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol 196:1732-40
Ní Cheallaigh, Clíona; Sheedy, Frederick J; Harris, James et al. (2016) A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling. Immunity 44:368-79
Tzeng, Te-Chen; Schattgen, Stefan; Monks, Brian et al. (2016) A Fluorescent Reporter Mouse for Inflammasome Assembly Demonstrates an Important Role for Cell-Bound and Free ASC Specks during In Vivo Infection. Cell Rep 16:571-582
Yang, Huan; Wang, Haichao; Ju, Zhongliang et al. (2015) MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 212:5-14
Janssen, Erin; Ozcan, Esra; Liadaki, Kyriaki et al. (2014) TRIF signaling is essential for TLR4-driven IgE class switching. J Immunol 192:2651-8
Davaro, Facundo; Forde, Sorcha D; Garfield, Mark et al. (2014) 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1? interferes with mature IL-1? signaling. J Biol Chem 289:16214-22
De la Fuente, Marjorie; Franchi, Luigi; Araya, Daniela et al. (2014) Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. Int J Med Microbiol 304:384-92
Levitz, Stuart M; Golenbock, Douglas T (2012) Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284-92

Showing the most recent 10 out of 22 publications